0      0

JL1112EH - JL1112EH: Metabolic response rates of epcoritamab + R-CHOP in patients with previously untreated (1L) high-risk diffuse large B-cell lymphoma, including double-hit/triple-hit lymphoma: Updated EPCORE NHL-2 data

‐ Oct 23, 2023 3:00pm

Full author listing

Lorenzo Falchi, MD,1* Michael Roost Clausen, MD, PhD,2 Fritz Offner, MD, PhD,3 Sven de Vos, MD, PhD,4 Joshua Brody, MD,5 Kim M. Linton, MBChB, PhD,6 Sylvia Snauwaert, MD, PhD,7 Raul Cordoba, MD, PhD,8 Jun Wu, MD, MS,9 Irina Bykhovski, PharmD,10 Liwei Wang, PhD,10 Ali Rana, MD, PhD,10 David Belada, MD, PhD11

1Lymphoma Service, Memorial Sloan Kettering Cancer Center, New York, NY, USA; 2Vejle Hospital, Vejle, Denmark; 3Universitair Ziekenhuis Gent, Ghent, Belgium; 4Ronald Reagan University of California Los Angeles Medical Center, Los Angeles, CA, USA; 5Icahn School of Medicine at Mount Sinai, New York, NY, USA; 6The Christie NHS Foundation Trust and Manchester Cancer Research Centre, Manchester, UK; 7Department of Hematology, AZ Sint-Jan Hospital, Bruges, Belgium; 8Fundacion Jimenez Diaz University Hospital, Health Research Institute IIS-FJD, Madrid, Spain; 9AbbVie, North Chicago, IL, USA; 10Genmab, Princeton, NJ, USA; 114th Department of Internal Medicine – Hematology, University Hospital and Faculty of Medicine, Hradec Králové, Czech Republic

*Corresponding author.